Alan Tan, MD

Alan Tan, MD, is an associate professor of medicine in the Division of Hematology Oncology at Vanderbilt University Medical Center and a genitourinary oncology and melanoma specialist at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.

Articles by Alan Tan, MD

Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

ByUlka Vaishampayan, MD,Alan Tan, MD,Laurence Albiges, MD, PhD,Neeraj Agarwal, MD,Matthew T. Campbell, MD, MS,Benjamin Maughan, MD, PharmD

November 14th 2023

Renowned oncologists discuss the case of a 75-year-old man with advanced renal cell carcinoma, providing insights into evaluation and frontline therapy choices.

Dr Tan on the Potential Utility of ctDNA in RCC

ByAlan Tan, MD

November 11th 2023

Alan Tan, MD, discusses the ongoing investigation and potential utility of circulating tumor DNA in patients with renal cell carcinoma.

Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

ByUlka Vaishampayan, MD,Laurence Albiges, MD, PhD,Neeraj Agarwal, MD,Matthew T. Campbell, MD, MS,Benjamin Maughan, MD, PharmD,Alan Tan, MD

October 30th 2023

Explore statistics behind and possible patient presentations of advanced renal cell carcinoma (RCC), with insight into IMDC risk stratification that may influence treatment strategies and outcomes.

Alan Tan, MD

Articles by Alan Tan, MD

Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

Dr Tan on the Potential Utility of ctDNA in RCC

Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma